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1. Introduction 
In the report of the Experts of the World Health Organisation and the Food and Agriculture 
Organisation [1] which reviewed research results concerning the influence of lifestyle, 
particularly diet components on the risk level of diet-dependent diseases, beta-glucan was 
acknowledged as a substance limiting the risk of many the so-called civilisation diseases. 
Simultaneously, it was recognized that the physiological influence of dietary fibre and 
interactions with other diet components are not fully known, therefore, further research 
within the scope is reasonable. Among various fractions of dietary fibre, β-glucans from 
cereals are especially significant, as they are considered safe and at the same time 
recommended for intake as food components lowering total cholesterol concentration in 
blood. Unlike widely-known fractions of dietary fibre, recommended as a factor modifying 
and preventing the risk of circulatory system and digestive system diseases, beta-glucans 
show multidirectional and still not entirely recognized health influence [2]. 
β-glucans discovered so far have been used in the pharmaceutical industry as substances 
strengthening the immune system, preparations of antiviral and antibacterial activity, and 
as natural adjuvants, which resulted in them being called “biological response modifiers” 
(BRMs). It is assumed that substances of this type cannot do harm, they help the body to 
adjust to various environmental and biological stresses and have a regulating and multi-
directed influence on the body, most of all, supporting the immune system, but also 
showing another positive influence on some functions of the body, e.g. correcting lipid 
metabolism, correcting glycemic index in people with type 2 diabetes, or exhibiting 
antitumor activity [3].  
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2. Sources and general properties of β-glucans  
β-glucans are long-chain, multidimensional polymers of glucose, in which particular 
particles of glucopyranose are linked with glycosidic bonds of β type, linearly, in (1→3) 
and/or (1→4) structure or in a branched way, i.e. with side chains of varied length, linked 
to the main core with glycosidic bonds of β-(1→6) type. They are structural components of 
plant cell walls (mostly cereals – oats and barley), yeast (Saccharomyces cerevisiae, 
Saccharomyces fragilis, Candida tropicalis, Candida utilis among others), as well as the so-
called Chinese or Japanese fungi. Also beta glucans constituting the components of cell 
walls, or being the excretion of various bacteria (e.g. Alcaligenes faecalis var. Myxogenes, 
Cellulomonas flavigena Bacillus or Micromonospora) [4] are known. The presence of β-glucans 
have also been confirmed in the cell walls of some vegetables (carrot, radish, soybean) and 
fruit (bananas) [5]. 
β-glucans isolated from fungi seem to be the most advantageous, i.e. of greatest pro-health 
influence. β-glucans from cereals are quite well-known. Present interest in isolating β-
glucans takes into account new sources of β-glucans, e.g. baker’s yeast Sacharomyces 
cerevisiae, considered a better source than cereals or fungi in terms of economics.  
The pro-health influence of beta glucans on the body depends on their physicochemical 
properties. The physicochemical properties of β-glucans differ depending on characteristics 
of their primary structure, including linkage type, degree of branching, molecular weight, 
and conformation (e.g. triple helix, single helix, and random coil structures) [3,4]. 
Native β-glucans, depending on their origin contain different bonds, show varied solubility 
degree and varied direction of pro-health influence. Beta glucans from: 
- cereals – containing (13)-(14)-β bonds and constituting main soluble fractions, serve 
as dietary fibre, of a particularly important function aiming to lower cholesterol 
concentration and triacyloglycerols in blood, 
- yeast - containing (13)-(16)-β bonds and constituting usually insoluble forms. They 
are known for their enhancing the immune system, by activating first of all macrofags. 
They also stimulate the skin cell response to combat free radicals and defend against the 
environmental pollution, significantly delaying aging process, and act anti-
inflammatory. 
- fungi – contain both (13)/(16)-β and (13)/(14)-β type bonds, from which 53-83% 
constitute insoluble fractions and 16-46% - soluble fractions. They are called 
heteroglucans showing universal immunostimulating and immunomodulating activity 
of antiviral, antibacterial and antiallergic character. They also have the ability to lower 
high blood cholesterol, inhibit excessive cholesterol synthesis and remove the excess of 
glucose from peripheral blood. Beta glucan activity as an anti-tumour factor concerns 
mostly (13)-(16)-β forms. 
A lower level of branching and lower polymerisation degree are characterised by better 
solubility (Fig. 1). It is believed that insoluble β-glucans are those whose degree of 
Spent Brewer’s Yeast and Beta-Glucans Isolated from Them as Diet Components  
Modifying Blood Lipid Metabolism Disturbed by an Atherogenic Diet 
 
263 
polymerisation (DP) is higher than 100 [6]. Insoluble or slightly soluble beta glucans contain 
very long, multi-branched side chains in the particle (Fig. 2). 
 
 
Figure 1. An example of the molecular structure of soluble yeast β-glucan. 
Molecular weight of beta glucans obtained from various sources differs within a wide range 
of values from 0,2 x 101 kDa to 4 x 104 kDa. From technological point of view, beta glucans of 
high molecular weight (> 3 x 103 kDa) are characterised by high viscosity, and those of low 
molecular weight (about 9 kDa) constitute gels. Hydrolysed beta-glucans are soluble, but 
not very viscous and do not constitute gels.  
Physicochemical properties of β-glucans might be modified through the use of various 
technologies during their isolation. Used chemical or enzymatic methods, leading to the 
hydrolysis of long-chain β-glucans, allow to lower the degree of depolymerisation and their 
particle mass in relation to native form, which simultaneously increases their solubility and 
lowers viscosity in liquids [7]. 
Among many methods leading to depolymerisation of long-chained and multi-branched β-
glucans, it is essential to distinguish other chemical modifications, e.g. esterification [8], 
phosphorylation [9], sulphonation [10], chlorosulphonation [11], or carboxylmethylation 
[12]. This last method is considered to be one of the most effective methods transforming 
insoluble forms into soluble fractions [13]. All authors state, however, that introducing an 
additional functional group to β-glucan chain might lead to simultaneous growth of glucan 
particle size, which in turn leads to excessive increase in their viscosity in water solution, 
and therefore, shows different than expected physiological influence [14]. There is also 
research published showing that viscosity of β-gluccans depends to a large extent on the 
degree of purification during their isolation [15]. 
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Figure 2. An example of the molecular structure of insoluble yeast β-glucan.  
2.1. β-glucans isolated from cereals 
Among cereals, the greatest amount of β-glucan in relations to dry mass can be found in 
barley grains (3-11%) and oat grains (3-7%). Small quantities of β-glucans are also found in 
rice (about 2%), wheat (about 1%) and sorghum (0.2-0.5%) [11]. In case of oat, β-glucans are 
present mostly in external layers of the grain, whilst in barley grain, these substances are 
spread evenly in the entire grain.  
Unlike insoluble cellulose, whose glucose particles are linked linearly with -D-(1→4) 
bonds, β-glucans contained in the endosperm of cereals grains are the mixture of -D-
glucose unbranched chains linked with -(1→3) and -(1→4) glycosidic bonds (Fig. 3) [16].  
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Figure 3. Primary molecular structure of (1-3)/(1-4)-β-glucan from barley grain. 
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Slightly different properties are characteristic of β-glucans isolated from sorghum, in which 
all three types of chains, i.e. both β-(1→3)-, β-(1→ 4)-, and β-(1→ 6) [17] have been found. In 
β-glucans isolated from most cereals β-(1→3) bonds constitute about 30%, whilst β-(1→4) 
bonds - about 70% of all bonds, with slight deviations characteristic of particular cereals [18]. 
β-glucans from oat are known as substances of pro-health influence comparable to β-
glucans isolated from barley [19], particularly in the ability to lower glucose concentration in 
blood [20], total cholesterol and triacylglycerols in blood [21,22].  
β-glucans extracted from cereals, which mainly contain β-(1,3-1,4)-d-glucan, have been 
demonstrated to reduce blood lipid levels, including cholesterol and triacylglycerols levels. 
The mechanisms by which β-glucans from cereals reduce blood lipid levels have been 
shown to include prevention of cholesterol reabsorption by adsorption, elimination of bile 
acid by adsorption, an increase in bile acid synthesis, and suppression of hepatic cholesterol 
biosynthesis by short-chain fatty acids produced by fermentation with intestinal bacteria 
[23,24].  
2.2. β-glucans isolated from fungi 
There are ”medicinal” fungi, used in traditional medicine of the countries of the East [25], 
such as Chinese Reishi (Ganoderma lucidum), or Japanese Shiitake (Lentinula edodes) and 
Maitake (Grifola frondosa), arboreal fungi: Chaga (Inonotus obliquus), Turkey Tail (Trametes 
versicolor), Split Gill (Schizophyllum commune), Mulberry Yellow Polypore (Phellinus linteus) 
and cultivated, e.g. Hiratake (Pleurotus ostreatus, Oyster mushroom). The concentration of β-
glucans in Basidiomycota fungi is relatively low and ranges from 0.21 to 0.53 g/100 g of dry 
mass [26].  
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Figure 4. Primary molecular structure of lentinan from Lentinus edodes. 
β-glucans isolated from fungi are heteroglucans containing both (13)/(14)-β and 
(13)/(16)-β bonds. They usually constitute the mixture of insoluble (about 53-83% 
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participation) and soluble (about 16-46%) fractions [40] of varied properties. They are mostly 
known as factors stimulating the immune system, having antiviral, antimicrobial and 
antiallergic properties [27,28]. They also have the ability to lower high blood pressure, slow 
down the excessive cholesterol synthesis and lower glucose concentration in blood [29], as 
well as show antioxidating properties [23]. They are also known as substances of anti-
tumour properties [4]. β-glucans well-known in terms of structure and biological activity are 
identified in accordance with their names, e.g.: lentinan (Fig. 4) obtained from Lentinus 
edodes, schizophyllan (SPG) (Fig. 5A) from Schizophyllum commune, pleuran from Pleurotus 
ostreatus or pullulans (AP-FBG) (Fig. 5B) from Aureobasidium pullulans, scleroglucan (SGG) 
(Fig. 6) from Sclerotium rolfsii, grifolan (GRN) from Grifola frondosa, krestin (PSK - 
polysaccharide-K and PSP - polysaccharopeptide) from Coriolus versicolor [30-34]. 
 
Figure 5. Primary molecular structure of Schizophyllan (A) from Schizophyllum commune and pleuran 
(B) from Aureobasidium pullulans. 
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Figure 6. Primary molecular structure of scleroglucan from Sclerotium rolfsii. 
Recently characterized structure of a novel water-soluble polysaccharide (ZPS - Zhuling 
polysaccharide) from the fruit bodies of medicinal mushroom Polyporus umbellatus and 
investigate its immunobiological function [35]. 
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2.3. β-glucans isolated from bacteria  
Polysaccharides of bacterial origin are known and widely used in food industry mostly as 
additives. They are often called bacterial egzopolisaccharides and constitute the ingredient 
of the cell wall, or can be excretions of various microorganisms, such as: Cellulomonas 
flavigena of KU strain [36], Bacillus curdlanolyticus and Bacillus kobensis [37], Bacillus and 
Micromonospora [38] Agrobacterium spp. ATCC31749 [39], Bradyrhizobium, Rhizobium spp. 
Sarcina ventriculi [40].  
The ones mass produced and used are: xanthan, dextran, pullulan or gellan. β-glucans of 
bacterial origin have the structure similar to mannans, but glucose constitutes their basic 
unit building block. Mucilages called xanthans produced by Xanthomonas campestris bacteria 
pathogenic for plants are widely used. Beta glucans produced as a result of microbiological 
fermentation called curdlan (Fig. 7) and laminarin are known from technological point of 
view. 
 
Figure 7. Primary molecular structure of (1-3)-β-glukan (A – curdlan; B - laminarin). 
Dextran is a glucan synthesized from saccharose by Leuconostoc mesenteroides and Streptococcus, 
containing glucose particles connected most often with (1→6) bonds of α type [41].  
Microorganisms used in food industry, mostly lactid acid bacteria (LAB) are a rich source of 
egzopolisaccharides [42].  
2.4. β-glucans isolated from Saccharomyces cerevisiae  
Yeast, both baker’s and spent brewer’s yeast, are characterised by high concentration of beta 
glucans, amounting on average to 7.7%, located in the cell wall. Cell wall (constituting 15-
30% of dry mass of yeast cells), is a complex, multi-particle structure, consisting in 50-60% of 
β-glucans and in about 40% of mannoproteins. Natural β-glucans isolated from yeast are 
insoluble in water, and their insolubility is caused by chitin, a polisaccharid consisting of 
residues of N-acetyl-glucosamine, linked with (1→4)-β-glycosidic bonds (chitin amounts to 
about 1% of cell wall mass). Chitin complex–(1→3)-β-glucan (about 3-9% of cell wall mass), 
is located on the inside of cell wall (1→6)-β β-glucan branches, link particular components of 
cell wall with the use of mannoproteins and covalent bonds. Mannoproteins are located on 
the outside of yeast cell wall [43]. 
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Sparse research on β-glucans isolated in the laboratory from cell walls of baker’s yeast 
Saccharomyces cerevisiae, shows varied biological activity depending on the used technology 
of their isolation. They can strengthen the immune system, show antioxidant properties, and 
delay the process of cell aging [23,44]. 
Due to a high content of β-glucans in spent brewer’s yeast Saccharomyces cerevisiae, 
remaining after alcohol fermentation in the process of beer production, it seems that they 
can be an effective and inexpensive material for obtaining β-glucan preparations.  
Fig. 8 presents the diagram showing the use of spent brewer’s yeast, which constitute 
troublesome waste for the brewing industry.  
 
Figure 8. The possibilities of using spent brewer’s yeast Saccharomyces cerevisiae. 
Beta glucans might be obtained as a byproduct in the production of preparations enhancing 
flavour (yeast extracts), and the remains after fibre extraction constitute a good material for 
obtaining beta glucans. 
So far no research has been conducted on pro-health β-glucans obtained from spent 
brewer’s yeast Saccharomyces cerevisiae, which constitute a natural, often a troublesome 
byproduct of the brewing industry, waste product after alcohol fermentation in beer 
production. Sparse research on β-glucans obtained from this type of material is conducted 
on a laboratory scale and aims mostly to examine their technological properties, 
conditioning their usage as additional substances of thickening, gelling and/or water 
binding properties.  
3. The purpose and scope of work 
This work has aimed to assess pro-health activity of β-glucans isolated from a new, 
uninvestigated within this scope source, i.e. spent brewer’s yeast Saccharomyces cerevisiae. 
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Functional properties, i.e. physico-chemical properties of dried spent brewer’s yeast and β-
glucans isolated from them have been characterized. In order to determine the influence of 
glucan preparations (soluble BG-CMG and native - insoluble BG-HP) and spent brewer’s 
yeast on the lipid metabolism of the rat body, examined preparations have been added to 
atherogenic diet of animals (1% of cholesterol and 20% of fat) in such an amount so as to 
obtain the following levels: 
a. for β-glucans: 10 and 100 mg/kg of body mass - the dose of 10 mg/kg body mass is the 
amount calculated for an adult weighing 70 kg - 700 mg per day, the dose 100 mg/kg 
body mass – 7 g per day, 
b. Spent brewer’s yeast were added in the amount 100 mg daily (0.5% of diet components, 
which is about 500 mg/kg body weight). This amount corresponded to the intake of 
beta-glucans from spent brewer’s yeast in an amount of 10 mg/kg body weight. 
The research has been conducted in relation to control group, which has not been given 
yeast preparation additive.  
4. Research material and conditions of biological experiment 
Material consisted of: 
- dried, spent brewer’s yeast Saccharomyces cerevisiae - from INTER YEAST company, 
constituted the research material (Content: Protein - 43.5%, fat - 4% Total Carbohydrates 
- 25%, squalene - 125 mg per 100 g of powder, beta-glucan - 1.9%), 
- commercial, pure beta glucans isolated from spent brewer’s yeast (from the yeast cell 
walls): insoluble BG-HP (Beta HP(1/3)-(1/6)-β-D-Glucane Powder), 
- and soluble carboxymethylglucan BG-CMG (Beta CMG: 92% β-1,3/1,6-D-glucan 
concentration, 1.2% protein, <0.6% of mannans and <0.5% chitin), were provided by 
German company LEIBER GmbH - INTER YEAST. 
4.1. Biological experiment and its progress 
The experimental animals were growing male rats (Wistar) with an initial body weight of 
about 100 g. Prior to the start of the experiment, animals were given water and commercial, 
standard rat food LSM® ad libitum for 7 days to adapt them to the experimental conditions. 
Later the animals were randomly divided into 6 groups (7 rats in one group) in relation with 
diet composition:  
a. Control - without β-glucans,  
b. BG-CMG - with carboxymethylglucan: 
 BG-CMG10 (10 mg/kg of body mass), 
 BG-CMG100, (100 mg/kg of body mass), 
c. BG-HP - with insoluble beta glucan: 
 BG-HP10 (10 mg/kg of body mass), 
 BG-HP100 (100 mg/kg of body mass), 
d. and SBY – with dried spent brewer’s yeast.  
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The average body mass of rats in each group was similar. Diets (semisynthetic, isocaloric) 
were prepared in accordance with the recommendations of the American Institute of 
Nutrition [45]. Mineral mixture AIN-93G-MX and vitamin mixture AIN-93G-MV were used. 
The composition of experimental diets is presented in Table 1.  
The research was conducted on control group, which did not receive beta glucan additive. 
Diet intake and body weight growth of research animals were controlled during the 
research. Ethics Committee approved of the research. Energy derived from fat, protein and 
carbohydrates was 40.1; 15.8 and 44.1%, respectively.  
 
Components 
Diet 
Control 
BG-
CMG10 
BG-
CMG100 
BG-HP10 BG-HP100 SBY100 
Wheat starch, g 49.0 49.0 49.0 49.0 49.0 48.5 
Casein, g 20.0 20.0 20.0 20.0 20.0 20.0 
Soya oil, g 20.0 20.0 20.0 20.0 20.0 20.0 
α-cellulose, g 5.0 5.0 5.0 5.0 5.0 5.0 
DL-methionine, g 0.3 0.3 0.3 0.3 0.3 0.3 
Choline bitartrate, g 0.2 0.2 0.2 0.2 0.2 0.2 
Mineral mix, g  3.5 3.5 3.5 3.5 3.5 3.5 
Vitamin mix, g 1.0 1.0 1.0 1.0 1.0 1.0 
Cholesterola/, g 1.0 1.0 1.0 1.0 1.0 1.0 
Spent brewer’s yeast, g 0 0 0 0 0 0,5 
β-glucans from spent 
brewer’s yeast, mg/kg 
of body mass/dayb/: 
0 10 100 10 100 0 
Protein, g/100 g of diet 
(% of EV) 
18.0 (15.8%) 18.1 (15.9) 
Fat, g/100 g of diet  
(% of EV) 
20.3 (40.1%) 20.3 (40.2) 
Carbohydrates, g/100 g 
of diet (% of EV) 
50.2 (44.1%) 49.9 (43.9) 
Energy value (EV), 
 kJ (kcal) 
1904 (455,5) 1900.5 (454.7) 
Table 1. Composition of 100 g control and model diet enriched with β-glucans.  
a/ Sample weight of prepared earlier diet were mixed with fresh cholesterol in the proportion 99:1, 
directly before being served to animals; b/ β-glucans were weighed in the amounts adequate for each 
rat’s body mass, then mixed with small diet portions (5 g) and given to each animal individually. After 
having eaten, the animals were served diet and water ad libitum. 
During the whole experimental period (6 weeks) rats were housed in individual cages with 
24 h access to water. The premises, in which the experimental rats were housed had a 12:12h 
light cycle with temperature of 21-22oC and humidity of 55-65%. The proper experiment 
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lasted 6 weeks, after which blood from myocardium was collected. Animals were put to 
sleep with the peritoneal injection of Thiopental. 
4.2. Research methods 
4.2.1. Particle size and swelling ability  
The size of particles was analysed with the method of laser difraction with the use of 
Mastersizer S analyser of Malvern Instruments Ltd., Malvern, Great Britain. Particle size 
distribution of examined preparations was measured using the wet process in oil emulsions 
and/or water solutions of concentration within the range of 0.01 – 0.05%. 
4.2.2. Viscosity of water solutions 
Rheometric measurements were conducted with the use of rheo-viscometer of Brookfield 
DV III+ using ULA spindle and DIN-82. Measurement device was coupled with 
RHEOCALC for Windows version 2.l. computer programme, from which dynamic viscovity 
values were read at varied shear velocity. 
4.2.3. Antioxidant properties of preparations with in vitro method 
Antioxidant properties of preparations were marked with spectrophotometric method with 
the use of synthetic radicals ABTS+ [46]. Antioxidant activity of examined preparations was 
expressed as the ability of an examined preparation to de-activation of cation radicals 
ABTS+ and as TEAC (Trolox Equivalent Antioxidant Capacity), i.e. µM of Trolox for 1g of 
preparation.  
4.2.4. Lipid content 
Total lipid content was marked with a modified method of Folch et al. [47]. 
Total cholesterol - methyl esters have been prepared, from which 0.5% of the solution 
has been made using toluene as solvent. 1µl was collected from prepared solutions, 
which was dosed with a µ-syringe on the Hewelett-Packard HP 6890 Series GC System 
Plus gas chromatographer with a flame ionization detector (FID) and capilary column 
with polar stationary phase of 30 m length. Stigmasterol produced by Sigma was used as 
a standard.  
Lipid fractions - particular lipid fractions: HDL-cholesterol, and triacylglycerols (TG) in the 
plasma (mmol/L) were enzymatically measured with INTEGRA analyser. The 
concentrations of LDL cholesterol (mg/dL) were calculated as LDL cholesterol = total 
cholesterol – HDL cholesterol - (triacylglycerols/5). Cholesterol was converted from mg/dL 
to mmol/L by multiplying by 0.0259. VLDL-cholesterol was calculated as 1/5 TG [48]. In 
order to calculate the amount of cholesterol expressed in mg/dl for mmol/l, 0.0258 multiplier 
was used. 
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Atherogenic index - atherogenic index was calculated as the relation of assessed lipid 
fraction (HDL-Chol or LDL-Chol) to total cholesterol content (Total-Chol). This index 
allowed for defining the changes of these fraction participation in relation to total 
cholesterol content.  
4.2.5. Statistical analysis 
Data is presented as means ± standard deviation (SD). Obtained results were statistically 
analysed with STATGRAPHIC programme for Windows (v. 4.1.). The data was analysed 
using one-way analysis of variance (ANOVA). When a significant F ratio was found, 
Tukey’s multiple-comparison tests were conducted. Differences were considered significant 
at P<0.05. 
5. Results and discussion 
5.1. Characteristics of physico-chemical properties of used preparations 
Preparations of pure β-glucans and the preparation of dried spent brewer’s yeast examined 
in this work have proven to be efficient in correcting blood lipid metabolism, which has 
been shown in biological experiment on rats, which were given atherogenic diet, containing 
20% of fat and 1% of cholesterol, and at the same time preparations of beta glucans: soluble 
(BG-CMG) and insoluble (BG-HP) or dried, spent brewer’s yeast (SBY). 
These preparations differed in physico-chemical properties, i.e. particle size, solubility, the 
ability of water absorption and viscosity. These properties had a significant influence on the 
final effects obtained after their use in the experiment.  
During the examination of distribution of particle size of powdered β-glucans in comparison 
with spent brewer’s yeast preparations, it has been established that BG-HP preparation 
contained 60% of all particles of 59.4 µm in diameter and only about 5% of about 5 µm in 
diameter. The preparation of soluble β-glucan BG-CMG contained at least three clusters of 
particles of varied size, i.e. appropriately 0.2 µm, 3.5 µm and 90.2 µm, whereas the majority 
of particles (about 20% of all) had a diameter of 90.2 µm. Dried spent brewer’s yeast were 
characterised by three groups of varied size, and their greatest share (over 40%) had the size 
of about 63.6 µm. Dried spent brewer’s yeast particles were similar in size to particles of β-
glucan BG-HP preparation.  
Table 2 presents the percentage cumulated participation of particles in preparation content 
(e.g. d5 means that 5% of particles has the size below the value shown in the table, d50 = 50% 
of particles has the size not exceeding the value presented in the table, etc.). 
Particles of all examined preparations absorbed water during hydration. Preparation of 
native β-glucan BG-HP from brewer’s yeast and dried spent brewer’s yeast did not dissolve 
or dissolved only partially creating unstable water solutions with the tendency to create 
residue. Water solutions of β-glucan BG-CMG preparations were very viscid (65.2 mPas for 
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1% water solution and 574.9 mPas for 3% solution), whereas the preparations of β-glucan 
HP preparations and dried spent brewer’s yeast, dissolved in water only partially, creating 
nonviscid or only slightly viscid solutions (0.4-1.4 mPas) - tab. 3. 
Preparations The size of particles in cumulated values (d) [µm] 
Xśr. [µm] 
 d5 d10 d25 d50 d75 d90 d95 
HP β-glucan 5.2 16.8 32.7 50.14 70.74 93.4 107.3 52.98 
CM β-glucan 0.2 0.48 2.24 17.0 67.7 133.6 174.6 44.62 
SBY 6.61 16.26 34.8 64.5 169.5 325 396.9 119.4 
Table 2. The comparison of cumulated distribution of particle size of examined β-glucans and 
powdered spent brewer’s yeast. 
β-glucan particles isolated from spent brewer’s yeast, in the initial phase of hydration 
increased their volume from 3 (soluble BG-CMG) to about 5 times (insoluble BG-HP). These 
glucans were characterised by the fact that in the final stage of hydration, these particles 
decreased. The increasing, and then decreasing sizes of particles in the initial stage of 
hydration, may constitute the proof of tearing hydrogen and covalency bindings of helix of 
pre-hydrated β-glucans.  
Preparation 
Viscosity for 10 RPM 
[mPas] 
The level of adjustment 
reliance [%] 
1% 3% 1% 3% 
β-glucan BG-CMG 65.2a ± 7.5 574.9a ± 36.3 96.0 ± 2.1 94.4 ± 4.7 
β-glucan BG-HP 1.4c ± 0.2 1.9c ± 0.1 90.0 ± 1.3 93.6 ± 0.9 
SBY 0.4d ± 0.04 1.5d ± 0.04 84.6 ± 4.7 90.9 ± 1.6 
Table 3. The characteristics of viscositya/ of 1% and 3% water solutions of β-glucan preparations in 
comparison with 1% and 3% viscosity of water solutions of spent brewer’s yeast.  
a/ identical letter signs in columns equal the lack of a significant difference between compared mean 
values 
Limited solubility in water of native β-glucan HP might be explained with the presence in 
the structure of long, side chains with bindings β-(1→6), which can cause high crystality and 
insolubility of this β-glucan [6]. 
Weak hydration of complex structure of helix of high molecular weight β-glucans is the 
reason for their mutual intermolecular interactions between β-(1→3)-D and β-(1→6)-D-
glucan bindings, of strenght exceeding the interactions between bindings of β-glucan and 
water particle bindings or another solvent. Lowering of degree of polymerisation of beta 
glucans with β-(1→3)/(1→6)-D-glucan bindings to DP below 20, results in the weakening of 
intermolecular interactions, therefore, creating new bindings between β-glucan particles and 
solvent, causing its dissolution [2,4].  
The apparent improvement of β-glucan solubility in water solutions, without polymer 
degradation, can be achieved by activities stabilizing their scattering in water environment. 
[49]. It is possible to achieve stable scattering of β-glucans in water solutions, e.g. through 
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microwave heating, with temperature range 100-121oC and increased pressure within 4-10 
min. Quite advantageous effects in the modification of physico-chemical properties of β-
glucans are also obtained while using ultrasounds, as the method does not change the 
chemical structure of polymer’s particle size, resulting only in the decrease in the particle 
size, through breaking of the most sensitive chemical bindings. This method is used to 
obtain the so-called micronized β-glucan preparations. The process of micronization 
improves the distribution and stability of slightly soluble powders in water environment. 
The method also leads to permanent reduction of solution viscosity. According to the 
definition in the Polish Pharmacopoeia, micronized powders should contain particles of 
average diameter below 10 µm, at admissible 20% particle content of up to 50 µm diameter.  
CMG β-glucan preparation of modified chemical properties is the example of β-glucan 
examined in this work. HP native beta-glucan obtained from spent brewer’s yeast underwent 
the process of carboxymethylation, and in turn led to obtaining BG-CMG β-glucan preparation 
of modified viscosity, dozen times higher than the viscosity of HP native β-glucan (tab. 3).  
Carboxymethylated β-glucan CMG strongly absorbed water creating solutions of very high 
viscosity and stability, but also not showing properties of sedimentation. Native HP β-glucan 
did not dissolve in water, created nonviscous solutions, and moreover, strongly sedimented. 
Higher viscosity of carboxymethylated CMG β-glucan than native HP β-glucan, despite 
comparable particle size, might be explained by the fact that carboxymethylated CMG β-glucan 
might be characterised by higher particle mass resulting from additional methyl groups 
contained in their structure, which in turn enabled ist stronger hydration and viscosity increase.  
Many biological experiments showed that the change of physicochemical parameters of β-
glucans as a result of chemical or enzymatic modification might lead to the change of their 
pro-health influence, changes in sensoric quality [50, 51], therefore, it is extremely important 
to conduct research in case of each newly obtained preparation. 
During the evaluation of bioactive substance properties very often the evaluation of 
antioxidant properties is conducted, which are also checked for native β-glucan HP and β-
glucan BG-CMG modified through carboxymethylation. The preparations of these β-glucans 
were characterised by varied antioxidant activity expressed as TEAC (the number of Trolox 
milimols for each 1 g of preparation) - Fig. 9.  
 
Figure 9. The antioxidant activity of β-glucan preparations in comparison with spent brewer’s yeast. 
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The preparation of spent brewer’s yeast showed over 50-100 times higher antioxidant 
activity than β-glucan BG-HP isolated from them and β-glucan BG-CMG subject to chemical 
modification. Such high antioxidant activity of spent dried yeast preparation might result 
from squalene contained in the preparation, whose presence was confirmed in parallel 
research at the rate of 125 mg per 100 g of powder.  
5.2. Blood lipid metabolism 
In numerous research conducted on animals and in clinical research on people, 
hypocholesterolemic influence of β-glucans of cereal origin containing (1→3)/(1→4)-β 
bindings has been proven. This influence has been confirmed in case of β-glucans isolated 
from fungi, containing (1→3)/(1→6)-β bindings, however, it has been weaker in comparison 
with cereal β-glucans. However, there is no literature data on the influence of β-glucans from 
spent brewer’s yeast on the lipid metabolism of both experimental animals and people [52, 53]. 
During biological experiment, animals given diets supplemented with β-glucans HP and 
CMG and dried spent brewer’s yeast grew at a comparable pace. Body mass of animals after 
the experiment ranged from 390.8 to 412.3 g, and daily growth ranged from 6.5 to 7.2 g. 
Slight differences between particular groups were not statistically significant. In the groups 
of animals receiving β-glucans or spent brewer’s yeast, feed efficiency ratio (FER) did not 
differ significantly and ranged from 0.36 to 0.38 (tab. 4). 
Group – experimental factor 
Diet intake 
[g/day] 
Feed efficiency ratio FER4/ 
CONTROL 18.1a ± 0.4 0.38a ± 0.03 
β-g
lu
ca
ns
 BG-CMG10 18.0a ± 04 0.38a ± 0.03 
BG-CMG100 17.7a ± 0.5 0.36a ± 0.03 
BG-HP10 17.7a ± 0.7 0.37a ± 0.04 
BG-HP100 17.9a ± 0.4 0.38a ± 0.02 
SBY – spent brewer’s yeast 17.9a ± 0.9 0.38a ± 0.03 
 SEM 2/ (p3/) 0.067 (0.710) 0.004 (0.874) 
Table 4. The comparison of intake and nutritious efficiency of diets supplemented with β-glucan 
preparations and spent brewer’s yeast1/ (n=63). 
1/ mean values ± standard deviation for n = 7 or 8, 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05, 4/ 
Feed efficiency ratio: body mass growth (g/day) x diet intake-1 (g/day)-1, identical letter signs in columns 
equal the lack of a significant difference between compared mean values 
Table 5 and Fig. 10-11 show the results determing the influence of β-glucans and dried spent 
brewer’s yeast on total cholesterol concentrationm HDL and LDL fraction cholesterol and 
triacylglycerols in rat blood plasma.  
Total cholesterol concentration in the blood of rats in control group, given a model 
atherogenic diet (1% cholesterol, 20% fat) amounted to 3.79 mmol/l and was significantly 
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higher than in all experimental groups. A significantly higher (p=0.043) concentration of 
LDL fractions (1.8 mmol/l) was also observed in the control group. Total cholesterol 
concentration in the blood of rats given β-glucans preparations from spent brewer’s yeast in 
the daily amount equalling 100 mg/kg of bady mass or preparation of spent brewer’s yeast 
ranged from 2.82 to 2.97 mmol/l.The differences between these three groups were, however, 
insignificant statistically. The concentration of LDL-cholesterol fraction ranged in these 
groups respectively from 1.09 to 1.11 mmol/l (tab. 5). 
 
Group – 
experimental factor 
Total cholesterol 
[mmol/l] 
Cholesterol fractions 
HDL [mmol/l] LDL [mmol/l] 
VLDL 
[mmol/l] 
 Control 3.79a ± 0.13 1.58a ± 0.15 1.80a ± 0.12 0.41a ± 0.03 
β-g
lu
ca
ns
 BG-CMG10 3.23bc ± 0.23 1.52ab ± 0.14 1.35bc ± 0.14 0.26bc ± 0.04 
BG-CMG100 2.95bc ± 0.17 1.51ab ± 0.12 1.11de ± 0.15 0.33bc ± 0.03 
BG-HP10 3.20b ± 0.38 1.56ab ± 0.15 1.31bc ± 0.23 0.31bc ± 0.05 
BG-HP100 2.82bc ± 0.38 1.38ab ± 0.19 1.10e ± 0.19 0.30ab ± 0.16 
SBY 2.97bc ± 0.36 1.39b ± 0.13 1.29bce ± 0.26 0.30bc ± 0.04 
SEM p = 0.0065 p = 0.415 p=0.043 p=0.0295 
Table 5. Selected lipid parameters of peripheral blood in experimental animals given atherogenic diets, 
supplemented with β-glucan preparations and spent brewer’s yeast preparation1/ (n=63). 
1/ mean values ± standard deviation for n = 7 or 8; 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05; 
identical letter signs in columns equal the lack of significant difference between compared mean values 
 
Figure 10. The degree of total cholesterol reduction in peripheral blood of experimental animals on 
atherogenic diets caused by diet supplementation with β-glucan preparations and spent brewer’s yeast 
(*/ identical letters indicate no significant difference). 
It was concluded that diet supplementation with spent brewer’s yeast preparation, 
contributed to achieving lower concentration of total cholesterol of 21.6%. In groups of 
animals given diets containing β-glucans in a daily dosage of 10 and 100 mg/kg of body 
mass, the concentration of total cholesterol in blood was lower than in control group of 
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22.2% (in the group with β-glucan BG-CMG100) and of 25.6% (in the group with β-glucan 
BG-HP100) – Fig. 10. In these groups, LDL-cholesterol fraction was respectively lower of 38.3 
to 39.1% in comparison with control group (Fig. 11).  
The type of β-glucans from spent brewer’s yeast (BG-CMG and BG-HP) did not influence 
significantly the level of total cholesterol in blood (p = 0.638), whereas their dosage (p = 
0.002) had a significant influence. In rats from control group on a model athrogenic diet (1% 
cholesterol, 20% fat), cholesterol of HDL fraction amounted to 41.7% of total cholesterol, and 
LDL fraction cholesterol – 47.5%. The use of examined preparations in diet supplementation 
caused changes in the configuration of these fractions leading to lowering the LDL fraction 
participation and increasing percentage participation of HDL fraction cholesterol. Changes 
of these fractions in total cholesterol (LDL-cholesterol fraction below 40% of total 
cholesterol), were particularly visible in groups of rats given CMG and HP β-glucan 
preparations from spent brewer’s yeast in the amount equalling 100 mg/kg of body mass 
daily.  
 
Figure 11. Reduction ratio of LDL and HDL-cholesterol fractions and triacylglycerols in peripheral 
blood of experimental animals on atherogenic diets caused by diet supplementation with β-glucan 
preparations and dried spent brewer’s yeast (*/ identical letters indicate no significant difference).  
Table 6 presents the ratios of atherogenic factors of examined preparations. The ratio of 
HDL fraction to Chol-C and HDL to LDL fractions, after the experiment completion was in 
each case significantly higher in comparison with control group, which suggests that each of 
the examined preparations, regardless of the type and dosage, significantly improves the 
lipid metabolism of animals given atherogenic diet. 
In groups with beta glucan participation, the concentration of triacylglycerols ranged from 
0.67 to 0.76 mmol/l plasma, i.e. was lower in the control group from 14.8 to 25.6% (tab. 7, Fig. 
10). 
Dried spent brewer’s yeast given to animals in a daily dosage of 100 mg/kg of body mass 
contributed to lower the concentration of TG in blood in relation to control group of 27.2% 
(p = 0,008) – tab. 7, Fig. 12.  
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Group – experimental factor 
Atherogenic factors 
HDL/Chol-C HDL/LDL 
CONTROL 0.42a ± 0.03 0.88a ± 0.12 
β-g
lu
ca
ns
 BG-CMG10 0.49bc ± 0.03 1.16± 0.15b 
BG-CMG100 0.52cd ± 0.04 1.39c ± 0.29 
BG-HP10 0.49bc ± 0.02 1.23bc ± 0.12 
BG-HP100 0.52d ± 0.03 1.36c ± 0.15 
SBY 0.47b ± 0.03 1.09b ± 0.15 
SEM2/ (p3/) 0.006 (0.0001) 0.035 (0.0001) 
Table 6. The comparison of atherogenic factors characteristic of blood of experimental animals given 
atherogenic diets with β-glucan additive and spent brewer’s yeast1/. 
1/ mean values ± standard deviation for n = 7 or 8; 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05; 
identical letter signs in columns equal the lack of significant difference between compared mean values 
Group – experimental factor TG – triacylglycerols [mmol/l] 
CONTROL 0.90a ± 0.07 
β-g
lu
ca
ns
 β-glucan BG-CMG10 0.72b ± 0.06 
β-glucan BG-CMG100 0.67b ± 0.04 
β-glucan BG-HP10 0.74b ± 0.02 
β-glucan BG-HP100 0.76b ± 0.04 
SBY – spent brewer’s yeast 0.66b ± 0.09 
SEM2 (p3) 0.019 (0.008) 
Table 7. Selected lipid parameters of peripheral blood of test animals on atherogenic diets, 
supplemented with β-glucans and the preparation of dried brewer’s yeast 1/. 
1/ mean values ± standard deviation for n = 7 or 8; 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05; 
identical letter signs in columns equal the lack of a significant difference between compared mean values 
 
Figure 12. The percentage of lowered (with regard to the control group) the concentration of 
triacylglycerols (TG) in blood plasma in rats on atherogenic diets supplemented with β-glucans and 
dried spent brewer’s yeast (*/ identical letters indicate no significant difference).  
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Two-factor analysis showed the lack of significant influence of the type of β-glucan (soluble 
and insoluble) (p=0.091). Also the dosage of these beta glucans did not influence the 
reduction ratio of TG in rat blood (p=0.786). 
Table 8 compiles the total content of lipids and cholesterol in liver of rats on atherogenic 
diets supplemented with β-glucans and dried spent brewer’s yeast. The content of lipids 
was presented both in the equivalent of the so-called wet tissue and dry mass, whereas 
cholesterol content was presented in the equivalent of wet tissue and in reference to total 
lipid content.  
Group – experimental 
factor 
Lipids Total cholesterol 
g/100 g of wet 
tissue 
g/100 g s.m. of 
the liver 
mg/1 g of wet 
tissue 
mg/g of lipids 
Control 20.9a ± 2.8 47.3bc ± 1.3 82.5a ± 7.5 432.1ab ± 23.7 
β-g
lu
ca
ns
 BG-CMG10 19.5a ± 3.3 42.0ab ± 2.7 69.9b ± 6.0 352.1c ± 42.6 
BG-CMG100 18.6a ± 3.5 39.6a ± 4.1 67.5bc ± 6.5 340.9c ± 26.4 
BG-HP10 18.4a ± 1.9 42.5ab ± 3.9 66.0bc ± 1.1 361.4c ± 28.1 
BG-HP100 18.7a ± 34 39.1a ± 3.7 65. 1bc ± 5.4 348.3c ± 38.8 
SBY 19.1a ± 2.7 43.4ab ± 4.4 65.1bc ± 5.0 369.1bc ± 30.1 
SEM2/ (p3) 0.110 (0.62) 0.513 (0.007) 14.4 (0.05) 8.16 (0.001) 
Table 8. The content of lipids and cholesterol in the liver of rats on atherogenic diets supplemented 
with β-glucans and dried spent brewer’s yeast.  
1/ mean values ± standard deviation for n = 5 or 6; 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05, 
identical letter signs in columns equal the lack of a significant difference between compared mean 
values 
Total lipid content in fresh liver mass of rats did not differ significantly (p=0.110) in all 
groups and ranged from 18.4 to 20.9 g/100 g of wet tissue. Statistical analysis showed that 
the type of tested β-glucans (p=0.287) did not influence the concentration of lipids in the 
liver, whereas significantly better effects were observed when a higher dosage (p=0.003) was 
used.  
In comparison with cholesterol level, it has been stated that neither the type (p=0,444) nor 
the amount of β-glucans (p=0.720) in the diet, significantly influence the cholesterol 
concentration in the liver. 
Table 9 presents the percentage participation of saturated fatty acids (SFA), 
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) in total lipid 
pool in livers. The concentration of these groups of fatty acids was not influenced by the 
used β-glucans, but by their dosage (p=0.018). 
The type of β-glucan from spent brewer’s yeast did not significantly influence the ratio of 
blood lipid parameters metabolism in rats on atherogenic diet containing 1% of cholesterol. 
The concentration of HDL-cholesterol fraction and triacylglycerols in rat blood in this case 
depended neither on the type of β-glucan nor its dosage.  
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Literature data shows that hypolipemic activity of cereal β-glucans depends on the particle 
size and therefore, particle mass [54]. Using beta glucans of higher viscosity and higher 
particle mass in diet supplementation gives a better hypocholesterolemic effect [55]. Particle 
mass is a significant factor influencing hypocholesterolemic effect of β-glucans, but also it is 
essential to pay attention to the method of its designation [56]. Due to the variety of 
methods used by different researchers, it is difficult to compare experiment results 
presented by various authors. Hypocholesterolemic effect in people, resulting from cereal β-
glucan intake also depends on the dosage, diet supplementation period and even the age of 
tested people. β-glucan intake in the dosage of 3 g daily for 4 weeks, reduced the cholesterol 
concentration in the blood of children and teenagers with mild hypercholesterolemia of 
about 6-7% [57]. After 40 days of consuming diet containing from 1 to 5% of β-glucan from 
barley, total cholesterol concentration was reduced of 39%, LDL cholesterol fraction of 61% 
and triacylglycerols of 21%. 
Group – 
experimental factor 
% fatty acids in total pool of lipids 
Saturated SFA 
Monounsaturated 
MUFA 
Polyunsaturated 
PUFA 
Control 20.8a ± 2.9 26.7a ± 2.2 48.6ab ± 3.7 
β-g
lu
ca
ns
 BG-CMG10 19.1abc ± 1.9 26.7a ± 0.6 44.8bc ± 2.4 
BG-CMG100 15.4c ± 1.0 31.7b ± 1.4 51.4a ± 0.7 
BG-HP10 19.2ab ± 4.2 28.7ab ± 4.0 44.6c ± 4.1 
BG-HP100 15.9bc ± 0.6 29.6ab ± 2.5 45.1bc ± 0.1 
SBY 15.9bc ± 0.4 27.0a ± 1.2 50.5a ± 0.7 
SEM2/ (p3/) 0.578 (0.023) 0.856 (0.0001) 0.841 (0.0001) 
Table 9. The percentage participation of fatty acids in total lipid pool of livers in experimental rats 
given β-glucan preparations and spent brewer’s yeast. 
1/ mean values ± standard deviation for n = 5 or 6; 2/ SEM – standard error mean; 3/ ANOVA, p < 0.05; 
identical letter signs in columns equal the lack of a significant difference between compared mean 
values 
Significant results were obtained also as a result of 5% supplementation of rats’ diet with β-
glucan from oyster mushroom (Ostreatus Pleurotus). Such a level in the low- and high-
cholesterol diet lowered the concentration of cholesterol, including LDL and VLDL cholesterol 
fractions, in both cases of about 30% in blood plasma and of about 50% in the liver, which was 
simultaneously connected with lowering of HMG - CoA reductase activity [58].  
This work has not confirmed significant differencies between hypocholesterolemic effect of 
carboxymethylated β-glucan (soluble, of higher particle mass) and native β-glucan 
(insoluble).  
The influence of β-glucans on lipid metabolism depends to a large extent on the size of their 
particles. The carboxymethylated β-glucan isolated in the laboratory from baker’s yeast 
Saccharomyces cerevisiae, had a very low hipocholesterolemic activity despite its good 
solubility and high viiscosity. It has been explained by authors by the fact that apart from 
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the process of carboxymethylation, β-glucan underwent additional depolymerisation of 
particles through the use of ultrasounds. It led to a significant lowering of its particle mass, 
and therefore, the direction of its pro-health influence was changed.  
In the research on humans using cereal β-glucans in the diet, an atherogenic factor was 
expressed as the ratio of HDL cholesterol to LDL cholesterol, in almost every case was 
increased in comparison with control group. A similar effect was obtained in the research 
described in this work. Diet supplementation with β-glucan isolated from spent brewer’s 
yeast and preparation of dried yeast influenced the value of HDL/Chol-total ratio and 
HDL/LDL ratio. In each case of diet supplementation, these ratios were significantly more 
advantageous than in control group, which used only atherogenic diet [59]. 
Dried spent brewer’s yeast given to animals in the diet in the amount of 0.5% diet, were as 
efficient as β-glucan preparations prepared from them and helped to lower the 
concentration in blood of: total cholesterol of 21.6%, LDL fraction – of 28.2% and 
triacylogliceroles of 27.2% in relation to control group.  
Available literature data concerning the influence of diet supplementation with yeast 
preparations as the source of dietary fibre concerns in most cases other types or species of 
yeast. In the research on obese men with hypercholesterolemia have shown that intake of 15 
g of fibre from spent brewer’s yeast (containing β-glucan) advantageously lowered the 
concentration of total cholesterol in blood, increasing the concentration of HDL fraction 
cholesterol. Simultaneously, the changes in the concentration of triacylogliceroles in blood 
were not observed. Authors, however, did not give the exact consitution of yeast fibre, 
which made it difficult to compare these results with the results obtained in this work [60].  
Lowering of the concentration of total cholesterol in blood of experimental animals, as a 
result of diet supplementation with yeast, might be the result of not only β-glucan contained 
in them, but also the presence of squalens [61]. The ability of correcting blood lipid 
metabolism as a result of diet supplementation with yeast might result from the prebiotic 
properties of both the whole dried yeast cells and beta glucans contained in them, thanks to 
which the composition of natural bacterial flora can be additionally corrected [62]. 
As the research results show, the degree of liver fatness was significantly influenced by the 
dosage of beta glucans from spent brewer’s yeast, whereas the solubility did not matter 
statistically. Both examined β-glucan preparations were given in daily dosage of 100 mg/kg 
of body mass, efficiently protected the liver against excessive fat layering.  
The type of β-glucans from spent brewer’s yeast and their amount used in the diet did not, 
however, influence the cholesterol concentration in the livers. In comparison with the 
control group, the participation of cholesterol in liver lipids was in each case significantly 
lower. Two-factor analysis of variance showed that the higher dosage of β-glucans in the 
diet, i.e. 100 mg/kg of body mass daily, contributed to higher concentration of 
polyunsaturated fatty acids (PUFA) in livers and simultaneously lower concentration of 
saturated fatty acids (SFA). The dosage of β-glucans did not significanlty influence the 
concentration of monounsaturated fatty acids (MUFA). The concentration of all these 
 
Lipid Metabolism 
 
282 
groups of fatty acids was not influenced by the type of used β-glucans. Dried spent brewer’s 
yeast, like β-glucans, also contributed to obtaining lower concentration of cholesterol in 
calculation for the wet tissue of the liver.  
Beta glucans, regardless of origin, serve as dietary fibre in the body of mammals, therefore, 
their hipocholesterolemic effect might be associated with the mechanism recognised for 
dietary fibre. The influence of soluble fractions of dietary fibre on the cholesterol 
concentration in the body is known, by binding bile acids in the intestine and consequently 
increases the amount of bile acids excreted in the feces. It results in decreasing the pool of 
bile salt able to take part in the synthesis of cholesterol in liver and disregulation of micellas 
in intestines, which hampers lipid absorption. Cholesterol is used in the synthesis of bile 
acids instead of lipoproteid synthesis, therefore, speeding its circulation, and its 
concentration in plasma lowers [63,64].  
Hipocholesterolemic effect of tested β-glucans might be also compared with the activity of 
known prebiotic (inulin) and oat fibre. Inulin while undergoing fermentation in large 
intestine influences the proportions of produced SCFA [65], decreasing the amount of 
produced octan, and increasing the level of propionic and butyric acid. It is especially 
advantageous, as octan acts as a simulator and propionian as inhibitor of cholesterol 
synthesis [66]. Research in vitro showed that propionic acid hampers cholesterol and fatty 
acid synthesis in the liver. It seems that the combination of increased excretion of bile acid 
with faeces and slight lowering of cholesterol synthesis in liver aims to lower total 
cholesterol concentration and LDL fraction in blood [67]. 
Supplementation of rat diets with β-glucan preparations from spent brewer’s yeast 
examined in this work and the preparation of dried brewer’s yeast contributes to 
advantegous lowering of cholesterol concentration in blood, at simultaneous achieving a 
more advantegous in relations to control group content of bowel microflora, connected 
particularly with increased numer of Bifidobacterium bacteria of lactid acid, which was 
shown in parallelly conducted research.  
It is quite difficult to explain the estimated mechanism of lowering cholesterol concentration 
under the influence of prebiotics. However, increased excretion of cholesterol with faeces 
through hampering the creation of easily digested fatty micellas has been suggested. In rats, 
increased excretion of cholesterol in faeces has been confirmed, and similar research 
presents this mechanism also in people. It is possible that some bacteria of lactid acid can 
assimilate cholesterol directly. There is proof that fructooligosaccharides (FOS) lower the 
synthesis of triacylglycerols in liver, however, so far the mechanism has not been identified.  
Similar significance to probiotics is also attributed to prebiotics. Prebiotics arouse even 
greater interest due to practical means – they are characterised by greater durability than 
probiotics, their activity is not conditioned by micorbe viability after intake and they might 
be added to many food products as one of the ingredients. There is little research available 
concerning the research on people, therefore, most conclusions have been drawn based on 
the research on animals. In rats, for example, after a 5-week inulin administration a 
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significant lowering of triacyloglicerole concentration was observed. In people, however, 
oligofructose administration for 4 weeks did not lead to lowering triacylogliceroles and 
cholesterol [68]. Especially strong influence of prebiotics on lowering VLDL fraction is 
suggested [69]. 
6. Conclusions 
No significant differences have been observed in hypocholesterolemic effect of soluble β-
glucan – (CMG) and insoluble native β-glucan (HP). The results showed that after 
hydration, carboxymethylated β-glucan CMG was characterised by higher viscosity and 
mean particle size amounting to about 90 µm, whereas particles of insoluble HP β-glucan, 
established nonviscous solutions of particle size amounting to about 50 µm and about 320 
µm. Examined β-glucans showed an effective hypocholesterolemic effect. It has been proven 
that they influenced lipid metabolism advantageously, especially in case of LDL fraction 
cholesterol and triacylglycerols (TG). An advantageous HDL/Chol-total factor and 
HDL/LDL factor has also been confirmed. Dried spent brewer’s yeast were given to animals 
in a daily dosage of 100 mg/kg of body mass were as efficient as β-glucans isolated from 
them and they lowered the concentration in blood of: total cholesterol of 21.6%, LDL fraction 
– of 28.2% and triacylglycerols of 27.2% in relation to control group. The research also 
proves that advantageous influence of yeast on lipid metabolism and their level in blood 
might be linked with prebiotic properties of yeast on lipid metabolism, as in the research 
simultaneously conducted by the Author, the advantageous composition of intestine 
microflora was observed (a higher number of lactid acid bacteria of Bifidobacterium type was 
obtained). 
High nucleic acid content in yeast (supplying from 12% to 25% of total nitrogen content) [70] 
limits their use as a traditional ingredient in human nutrition. It has been stated that the 
excess of nucleic acid in the diet of people and most monogastric animals is toxic and results 
in excessive accumulation of uric acid in organism, leading to arthritis. Therefore, it is 
recommended to consume their little portions as diet supplement supplying mainly 
vitamins from B group. 
Numerous research on fish proved that diet supplementation with yeast to a particular level 
(in the amount providing no more than 50% of proteins in the diet), does not show 
disadvantageous health effects, such as abnormal growth, improper nitrogen balance or 
liver diseases [71]. However, only lower diet intake was observed when spent brewer’s 
yeast constituted more than 25% of the diet [70] 
It seems that diet supplementation with dried spent brewer’s yeast S.cerevisiae in the amount 
of 0.5% of the diet contributed significantly to correcting possible disorders in lipid 
metabolism of rats on an atherogenic diet – it enhances lipid changes in organism, 
enhancing their parameters. 
During the research on hypocholesterolemic activity of 81 different yeast strains, showed 
hypocholesterolemic activity of spent brewer’s yeast of male Wistar rats with their  
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Figure 13. Probable mechanism of hypocholesterolemic effect of beta-glucans and spent brewer’s yeast 
Saccharomyces cerevisiae. 
participation of 10% in the diet [72]. The hypocholesterolemic activities of the yeast varied 
remarkably between strains. In contrast, brewer’s yeast and baker’s yeast, which have been 
predominantly used for food, did not exhibit hypocholesterolemic activity even when 
administered at concentration of 10%. Whereas, during the research on obese men with 
hypocholesterolemy it has been shown that the intake of spent brewer’s yeast considerably 
lowers the concentration of total cholesterol, increasing the concentration of advantageous 
fraction of HDL cholesterol when consumed in the amount supplying 15 g of fiber daily. 
Triacylglycerol concentration in blood did not change considerably [60]. The yeast-derived b-
glucan fiber significantly lowered total cholesterol concentrations and was well tolerated; 
HDL-cholesterol concentrations rose, but only 4 weeks after the fiber was stopped. Described 
varied hypocholesterolemic activity of various spent brewer’s yeast results among others 
from the kind of yeast and the amount of their supplementation in the diet. Advantageous 
lowering of cholesterol concentration in the blood of test animals due to diet supplementation 
with yeast can be caused by prebiotic properties of yeast, which corrects natural content of 
bacterial flora [61] or considerably high amount of squalens in yeast lipids [62].  
A probable mechanism of HP beta glucan and insoluble, dried brewer’s yeast influence 
presented in the diagram (Fig. 13) is associated with their advantageous influence on testine 
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peristlsis and lowering HMG (3-hydroxy-3-methylglutaryl) CoA reductase activity, since 
also lowering of cholesterol concentration in liver was obtained.  
The influence of soluble beta glucan fractions (CMG) on cholesterol concentration in the 
body was associated with the ability to bind bile acids in a small testine. It might have led to 
a decrease in bile salt pool able to participate in cholesterol synthesis in liver and 
disregulation of micellas creation in testine, which hampered lipid absorption. Cholesterol 
was then used to a larger extent in bile acid synthesis rather than lipoproteid synthesis, 
therefore, its concentration in blood plasma was decreased. CMG and HP β-glucans given in 
a higher dosage (100 mg/kg of body mass daily), protected the liver more efficiently against 
excessive fat layering. Dried spent brewer’s yeast also contributed to obtaining lower 
cholesterol concentration in liver in comparison with control group.  
7. Requests 
Present interest of consumers to a large extent concerns food that can be used in prevention 
of many diet-dependent diseases, whereas the interest of food industry is directed at the 
search for new ingredients of pro-health influence. The knowledge of functional properties 
of preparations containg β-glucans might be used to shape proper quality of food products 
for special purposes. 
β-Glucan is a valuable functional ingredient and various extraction techniques are available 
for its extraction. Choice of an appropriate extraction technique is important as it may affect 
the quality, structure, rheological properties, molecular weight, and other functional 
properties of the extracted β-glucan. These properties lead to the use of β-glucan into 
various food systems and have important implications in human health.  
Diet supplementation with β-glucans from spent brewer’s yeast and preparation of dried 
spent brewer’s yeast contributed to advantageous lowering of cholesterol concentration in 
blood and lowering lipid concentration in liver. The results described above allow for the 
formulation of the following conclusions: 
1. β-glucan preparations obtained from spent brewer’s yeast and dried spent brewer’s 
yeast show efficient biological activity, connected with the improvement of blood lipid 
profile and liver of experimental animals. 
2. Spent brewer’s yeast show a similar pro-health influence to β-glucans isolated from 
them, therefore, they can be a valuable and much cheaper diet suplement, correcting 
blood lipid metabolism disturbed by atherogenic diet. 
3. β-glucan preparations from spent brewer’s yeast (CMG and HP) given in higher doses 
(100 mg/kg of body mass daily), efficiently protect liver against excessive fat layering. 
Results obtained in the experiment described above with various yeast preparations are 
valuable, since they point out that β-glucans obtained from a new source, i.e. spent brewer’s 
yeast have a hypocholesterolemic effect, similarly to other glucans described in literature. 
Moreover, it has been shown that each of examined β-glucans isolated from spent brewer’s 
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yeast was as efficient. Final effect correcting lipid metabolism, particularly various fractions 
of lipids, was more connected with the dose, rather than physic-chemical properties. 
Health advantages contributing to significant cholesterol reduction in blood obtained in 
experiments on animals, might constitute the basis for assuming that similar influence will 
be observed in case of a human body. Therefore, it would be recommended to supplement 
human diet with β-glucans, particularly for people whose diet is abundant in fat and 
cholesterol. Spent brewer’s yeast constituting a serious problem for brewing plants (waste 
material), can be used successfully as a valuable source of beta glucans, which can be used 
as diet supplements or as food additives, e.g. in yoghurts, breakfast desserts or snacks.  
Currently conducted research is the continuation of a presented experiment. It shows that 
atherogenic diet supplementation with beta-glucans or spent brewer’s yeast contributed to 
simultaneous obtaining more advantageous content of testine microflara in relation to 
control group, connected with the increased number of lactid acid bacteria Bifidobacterium 
and Lactobacillus and limited growth frequency of disadvantageous yeast fungi Candida 
albicans. Conducted research on functional properties and biological experiment proves the 
complexity of β-glucan and other fibre preparation influence on experimental animals.  
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